Back to Search
Start Over
Monitoring
- Source :
- Oncotarget
- Publication Year :
- 2018
-
Abstract
- Osimertinib is efficacious in lung cancer patients with epidermal growth factor receptor (Serum/plasma fromThirteen patients were included. Median time on osimertinib treatment was 10.6 months with a median progression-free survival of 13.6 months. Best response to osimertinib was partial response (PR), stable disease (SD) or progression (PD) in 46.1%, 30.8% and 23.1% of patients, respectively.Most of the patients were paucisymptomatic at baseline. Symptom improvement was reported in 66.6% of responder patients; while symptoms remained stable in 75% of patients with SD, and 66% of patients with PD had clinical deterioration.Three patterns of T790M changes during osimertinib treatment were identified. T790 remained detectable with PD or a short-lasting SD in 15.4% of the patients. T790M disappeared in 69.2% of patients with PR or SD. T790M disappeared, despite clinical and/or radiographic progression in 15.4% of the patients.Changes of T790M in serum/plasma in
- Subjects :
- Correction
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 9
- Issue :
- 43
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.pmid..........4276c7bd6315665dc376f32f43e85a5a